eShowcase: ViewPoint 3.6
Tools for Clinical Trials Professionals
Software provides complete visibility into the regulatory submission process
Octagon Research Solutions, Inc. (Wayne, PA) recently announced an update to its enterprise submission process management solution. Viewpoint 3.6 streamlines the regulatory submission process by affording visibility into the planning and management of the drug submission process and allows users to track, manage, and compile any type of regulatory application.
Viewpoint 3.6 Resource Estimator, Reviewer, and Regulatory Dashboard have been upgraded to provide enhanced workflow estimation, collaboration, and project tracking across the submission life cycle. The new Web-based Reviewer allows content contributors to view and validate their documents in the context of a submission. This, Octagon says, lessens the possibility that clinical trial professionals will miss a submission date or file an incomplete or noncompliant eCTD submission.
ViewPoint 3.6
Octagon Research Solutions, (610) 535-6500, www.octagonresearch.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
